Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Anushka Bakshi

- PMLiVE

Takeda’s Qdenga becomes second dengue vaccine to receive WHO prequalification

Approximately half of the global population is at risk of mosquito-borne viral disease

- PMLiVE

AstraZeneca’s sipavibart shown to prevent COVID-19 in immunocompromised patients

Immunocompromised individuals account for about 25% of COVID-19 hospitalisations, intensive care unit admissions and deaths

- PMLiVE

UCB shares positive phase 3 results for Zilbrysq in generalised myasthenia gravis

Zilbrysq is the first C5 inhibitor to show a clinically meaningful reduction of fatigue in the rare autoimmune disease

- PMLiVE

Exploring medical education and why it relies on real-world research

Onyx Health's Head of Medical Education, Sarah Seilly, explains our approach to MedEd and the benefits of tailoring your own

Onyx Health

- PMLiVE

Sanofi gains rights to Fulcrum’s muscular dystrophy treatment in deal worth more than $1bn

Losmapimod is being investigated as a potential transformative therapy for the rare disease

Biogen Idec building

Biogen and Eisai announce rolling FDA submission for injectable version of Alzheimer’s drug

The Leqembi SC autoinjector could reduce the need for hospital visits and nursing care compared to IV administration

- PMLiVE

Roche announces FDA approval of self-collection solution for HPV screening

More than 13,000 people are diagnosed with cervical cancer every year in the US

- PMLiVE

Trial reveals promising results for radiotherapy/hormone therapy combination in prostate cancer

Further evidence is being sought from the phase 2 TRAP trial results through the larger STAR-SHIP study

- PMLiVE

Pioneering Paths: Women Leadership in Rare Disease

Rare diseases are often thought of as affecting one in 100,000 or one in 1,000,000 people, and that is true for some conditions. But there are many rare diseases that...

Medscape Education Global

- PMLiVE

Takeda gains exclusive option for AC Immune’s Alzheimer’s drug candidate in deal worth over $2.1bn

The agreement includes an option to licence global rights to the anti-amyloid beta immunotherapy

- PMLiVE

Sanofi, Pfizer and AstraZeneca commit €2.5bn investment to biomanufacturing projects in France

The investments are part of the wider €15bn investment for the Choose France event

- PMLiVE

Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

Haemophilia A accounts for up to 85% of the 1,125,000 global haemophilia cases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links